Major Bladder Procedures without CC/MCC DRG Reimbursement

DRG 655 includes major bladder procedures performed during an inpatient stay when no Complication or Comorbidity or Major Complication or Comorbidity is coded; it covers extensive surgical management of bladder disease. This grouping matters for inpatient reimbursement because it establishes the payment weight for high-resource urologic operations under Medicare's prospective payment system.

DRG 655 Overview

DRG 655 covers hospital admissions for major bladder procedures without Complication or Comorbidity or Major Complication or Comorbidity. Cases include significant surgical interventions on the bladder such as cystectomy or complex reconstructive procedures when no additional coded complications are present. This Diagnosis-Related Group is important for Medicare payment because it groups resource use for substantial urologic operations into a single inpatient reimbursement category. Accurate coding and documentation determine assignment to this DRG and thus the applicable Medicare inpatient payment.

Prospective randomized trials comparing perioperative surgical techniques and approaches for major bladder procedures (for example open versus minimally invasive/robotic cystectomy or different urinary diversion methods). These studies enroll patients undergoing major bladder surgery, often for muscle-invasive bladder cancer or benign indications requiring cystectomy, and evaluate intraoperative variables, complication rates, operative time, and short-term morbidity. Results inform surgeons and hospital administrators about procedure-related resource use, expected LOS, and complication profiles that drive DRG-based costs and reimbursement planning.
Comparative effectiveness studies assessing enhanced recovery after surgery (ERAS) protocols and bundled perioperative care pathways in patients receiving major bladder procedures. These observational or pragmatic trials examine multimodal analgesia, fluid management, early feeding and mobilization, and standardized discharge criteria across heterogeneous inpatient populations, measuring readmissions, post-discharge complications, and total cost of care. Payers and provider networks use this evidence to design care bundles and payment models that reduce variability, lower preventable complications, and optimize reimbursement under the DRG.
Longer-term outcomes and quality-of-life cohort studies following patients after major bladder procedures, focusing on functional outcomes (continence, sexual function), stoma or diversion-related complications, and health resource utilization up to 1–5 years post-discharge. These studies target survivors of major bladder surgery, including older adults with multiple comorbidities, tracking rehospitalizations, outpatient visits, and durable impacts on independence and long-term care needs. Findings are critical for payers and case managers to project long-term costs, post-acute care needs, and to align discharge planning and coverage policies with expected downstream utilization.

Prospective randomized trials comparing perioperative surgical techniques and approaches for major bladder procedures (for example open versus minimally invasive/robotic cystectomy or different urinary diversion methods). These studies enroll patients undergoing major bladder surgery, often for muscle-invasive bladder cancer or benign indications requiring cystectomy, and evaluate intraoperative variables, complication rates, operative time, and short-term morbidity. Results inform surgeons and hospital administrators about procedure-related resource use, expected LOS, and complication profiles that drive DRG-based costs and reimbursement planning.
Comparative effectiveness studies assessing enhanced recovery after surgery (ERAS) protocols and bundled perioperative care pathways in patients receiving major bladder procedures. These observational or pragmatic trials examine multimodal analgesia, fluid management, early feeding and mobilization, and standardized discharge criteria across heterogeneous inpatient populations, measuring readmissions, post-discharge complications, and total cost of care. Payers and provider networks use this evidence to design care bundles and payment models that reduce variability, lower preventable complications, and optimize reimbursement under the DRG.
Longer-term outcomes and quality-of-life cohort studies following patients after major bladder procedures, focusing on functional outcomes (continence, sexual function), stoma or diversion-related complications, and health resource utilization up to 1–5 years post-discharge. These studies target survivors of major bladder surgery, including older adults with multiple comorbidities, tracking rehospitalizations, outpatient visits, and durable impacts on independence and long-term care needs. Findings are critical for payers and case managers to project long-term costs, post-acute care needs, and to align discharge planning and coverage policies with expected downstream utilization.

OpenPayer

Summary & Overview

Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

DRG 655 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes